ArticleMediators of inflammation2026
Integrative Inflammation-Metabolism Indicator for Cardiovascular-Kidney-Metabolic Syndrome: Evaluating the C-Reactive Protein-Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInflammation plays a critical role in the onset and progression of cardiovascular-kidney-metabolic (CKM) syndrome. However, the optimal inflammatory biomarker that simultaneously reflects disease severity and predicts future progression of CKM remains unexplored.
methodsThis study utilized data from three nationally representative cohorts: National Health and Nutrition Examination Survey (NHANES), UK Biobank (UKB), and China Health and Retirement Longitudinal Study (CHARLS). In NHANES, three machine learning approaches were applied to identify the inflammatory biomarker most strongly associated with CKM stages. The association between this biomarker and CKM severity was validated in UKB and CHARLS. Its predictive value for CKM progression was examined in UKB and CHARLS with Cox proportional hazard models. Multiple sensitivity analyses were conducted to ensure the robustness of the findings.
resultsAmong 15 circulating inflammatory biomarkers, the C-reactive protein-triglyceride glucose index (CTI) was identified as the most informative indicator of advanced CKM risk. In the cross-sectional analyses, 8959 participants from NHANES, 208,625 from UKB, and 8550 from CHARLS were included. After adjustment for potential confounders, higher CTI levels were consistently associated with advanced CKM across the three cohorts (NHANES: odds ratio [OR] = 1.35, 95% confidence interval (CI): 1.20-1.48; UKB: OR = 1.55, 95% CI: 1.46-1.64; CHARLS: OR = 1.42, 95% CI: 1.28-1.60). In longitudinal analyses including 186,753 participants from UKB and 3673 from CHARLS, elevated CTI levels predicted an increased risk of incident advanced CKM (UKB: HR = 1.22, 95% CI: 1.17-1.30; CHARLS: HR = 1.21, 95% CI: 1.01-1.46).
conclusionsCTI emerged as the most robust inflammatory biomarker for assessing disease severity and predicting CKM progression among multiple candidates. Its reproducible associations across national cohorts support its utility for early detection and risk stratification, offering a basis to refine CKM management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.